Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
Public ClinicalTrials.gov record NCT00852540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA. Subjects aged 2 months and older will be treated with either topical retapamulin for 5 days or oral linezolid for 10 days. The primary endpoint is the clinical response at follow-up (7-9 days after the end of therapy) in subjects who have a MRSA infection at baseline. The primary population is the per-protocol MRSA population. It is anticipated that approximately 500 subjects may be enrolled in order to obtain approximately 105 subjects who have a baseline MRSA infection.
Study identification
- NCT ID
- NCT00852540
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 410 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 2 Months and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2009 (Type not available)
- Primary completion
- Jul 2010 (Actual)
- Completion
- Sep 2010 (Actual)
- Last update posted
- Mar 27, 2017
2009 – 2010
United States locations
- U.S. sites
- 53
- U.S. states
- 25
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | — |
| GSK Investigational Site | Birmingham | Alabama | 35235 | — |
| GSK Investigational Site | Bentonville | Arkansas | 72172 | — |
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | Paragould | Arkansas | 72450 | — |
| GSK Investigational Site | Bakerfield | California | 93301 | — |
| GSK Investigational Site | Bell Gardens | California | 90201 | — |
| GSK Investigational Site | Huntington Beach | California | 92647 | — |
| GSK Investigational Site | Long Beach | California | 90813 | — |
| GSK Investigational Site | Roseville | California | 95661 | — |
| GSK Investigational Site | Sacramento | California | 92585 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80909 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20037 | — |
| GSK Investigational Site | Atlantis | Florida | 33462 | — |
| GSK Investigational Site | Bay Pines | Florida | 33744 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33306 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| GSK Investigational Site | Miami | Florida | 33144 | — |
| GSK Investigational Site | Pensacola | Florida | 32504 | — |
| GSK Investigational Site | St. Petersburg | Florida | 33710 | — |
| GSK Investigational Site | Vero Beach | Florida | 32960 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33401 | — |
| GSK Investigational Site | Columbus | Georgia | 31904 | — |
| GSK Investigational Site | Macon | Georgia | 31217 | — |
| GSK Investigational Site | Savannah | Georgia | 31406 | — |
| GSK Investigational Site | Honolulu | Hawaii | 96813 | — |
| GSK Investigational Site | Honolulu | Hawaii | 96814 | — |
| GSK Investigational Site | South Bend | Indiana | 46601 | — |
| GSK Investigational Site | Overland Park | Kansas | 66215 | — |
| GSK Investigational Site | Louisville | Kentucky | 40217 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70112 | — |
| GSK Investigational Site | Grand Blanc | Michigan | 48439 | — |
| GSK Investigational Site | Jackson | Mississippi | 39216-4505 | — |
| GSK Investigational Site | Butte | Montana | 59701 | — |
| GSK Investigational Site | Omaha | Nebraska | 68114 | — |
| GSK Investigational Site | Omaha | Nebraska | 68131 | — |
| GSK Investigational Site | Brooklyn | New York | 11203 | — |
| GSK Investigational Site | Carlisle | Ohio | 45005 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74127 | — |
| GSK Investigational Site | Corvallis | Oregon | 97330 | — |
| GSK Investigational Site | Gresham | Oregon | 97030 | — |
| GSK Investigational Site | Portland | Oregon | 97210 | — |
| GSK Investigational Site | Hazleton | Pennsylvania | 18201 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15212 | — |
| GSK Investigational Site | Austin | Texas | 78734 | — |
| GSK Investigational Site | Dallas | Texas | 75204 | — |
| GSK Investigational Site | Dallas | Texas | 75390-9113 | — |
| GSK Investigational Site | Duncanville | Texas | 75116 | — |
| GSK Investigational Site | Fort Worth | Texas | 76107 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Layton | Utah | 84041 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22902 | — |
| GSK Investigational Site | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00852540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00852540 live on ClinicalTrials.gov.